|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 20.62 USD | -4.89% |
|
+2.59% | -21.51% |
| 07-31 | Fulgent Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026 | |
| 07-31 | Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FULGENT GENETICS, INC. | Medical & Diagnostic Laboratories | -4.89% | +2.59% | -21.51% | -8.15% | -75.13% | 567M |  |  | |
- Stock Market
- Stocks
- FLGT Stock
- Charts Fulgent Genetics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
